DPH Biologicals starts new chapter with management-led buyout

DPH Biologicals has announced a significant transition in its ownership structure, with a management-led buyout supported by an undisclosed private investment group. Under the continued brand of DPH Biologicals, the company will continue to develop its flagship product – TerraTrove SP-1. In 2023 the company launched RegenAphex, a regenerative technology platform for biological products, and completed the EPA-registration and OMRI approval of BellaTrove Companion Maxx ST, a biofungicide seed treatment. Additionally, the company’s TerraTrove Residuce has seen expanded sales, now used on over 1 million acres.

Mick Messman, the president and CEO of the company, expressed pride in the company’s impressive growth, fueled by proven science, robust field data, and strong industry relationships. The focus on biological products has positioned DPH Biologicals as a key player in a market that is increasingly favoring such solutions for their comprehensive benefits, including yield enhancement.

The company’s strategic partnerships have allowed to add over 30 new retail partners in the U.S. agricultural market. Looking ahead to 2024, DPH Biologicals is poised for further growth with an advanced pipeline of five novel biologicals set to commence sales.

A collaborative research venture with the University of Illinois Urbana-Champaign’s Crop Physiology lab, led by Dr. Fred Below, and the reorganization of its T&O and International businesses highlight the company’s commitment to innovation and global expansion. DPH Biologicals, with its team of expert scientists, agronomists, and territory managers, is well-positioned to continue its upward trajectory and international outreach, including a planned expansion into Brazil.